A repository containing scripts that have been created to leverage the toolkit found within the CCDC portfolio that are accessible via the CSD Python API. The purpose of this platform is to distribute ...

This package and its authors are not affiliated with MLB or any MLB team. This API wrapper interfaces with MLB's Stats API. Use of MLB data is subject to the notice ...

After discontinuing development of its lead asset, Fulcrum Therapeutics has provided more details on its restructure, with 48 of 57 employees headed out the door. Fulcrum Therapeutics’ restructure ...

Supported Releases: These releases have been certified by Bloomberg’s Enterprise Products team for use by Bloomberg customers. Experimental Releases: These releases have not yet been certified for use ...

Fulcrum has been left with no option but to abandon its ambitions for pociredir in SCD and “explore strategic alternatives.” (Photo by Sarah Silbiger/Getty Images) Fulcrum Therapeutics has scrapped ...

Fulcrum Therapeutics has begun a strategic review that may result in it getting sold, a move made after the company’s main medicine hit a possibly insurmountable obstacle. On Tuesday, Fulcrum ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The oral drug, pociredir, was being tested to treat sickle-cell disease, an inherited blood disorder that can trigger pain, anemia and organ damage and reduce life expectancy. Sign up here. Pociredir ...

Fulcrum Therapeutics (FULC) lost nearly 50% of its value in extended trading after the company disclosed plans to discontinue the development of its lead asset, pociredir, for sickle cell disease in ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...